Novartis

Regulatory update on GSK-Novartis three-part transaction

Thursday, January 29, 2015 12:25 PM

GlaxoSmithKline has received clearance from the European Commission (E.C.) of its proposed three-part transaction with Novartis, which includes the acquisition of Novartis’s vaccines business (excluding influenza vaccines), the creation of a consumer healthcare joint venture between GSK and Novartis and the divestment to Novartis of GSK’s marketed oncology portfolio, related R&D activities and rights to two pipeline AKT inhibitors.

More... »


Array to acquire Novartis BRAF inhibitor encorafenib (LGX818)

Friday, January 23, 2015 11:40 AM

Array BioPharma, based in Boulder, Colo., has reached a definitive agreement with Novartis Pharma to acquire worldwide rights to encorafenib (LGX818), a BRAF inhibitor currently in phase III development. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline on April 22, 2014, which are expected to close in the first half of 2015, and the agreement remains subject to the receipt of regulatory approvals.

More... »


FDA approves record 41 new drugs in 2014, over 40% for rare diseases

Friday, January 16, 2015 02:52 PM

Pharmaceutical innovation had a banner year in 2014, as the FDA approved 41 novel drugs and biologics—the largest number in 18 years and a 52% increase from the 27 approved in 2013.

More... »

Optum Labs adds five collaborators

Thursday, January 15, 2015 01:37 PM

Optum Labs, a Cambridge, Mass.-based collaborative research and innovation center co-founded by Optum and Mayo Clinic, has added five new collaborators committed to improving the quality and value of patient care. These include:

More... »

Qualcomm, Novartis collaborate to optimize global clinical trials

Wednesday, January 7, 2015 12:56 PM

Qualcomm Life, a San Diego, Calif.-based provider of device connectivity and data management for the medical device industry, has been selected by Novartis as a global digital health collaborator for its Trials of The Future program.

More... »

Intellia Therapeutics, Novartis partner

Wednesday, January 7, 2015 12:40 PM

Intellia Therapeutics, a Cambridge, Mass.-based developer of therapeutic products using CRISPR/Cas9 technology for gene editing and repair, has announced a five-year R&D collaboration with Novartis to accelerate the ex vivo development of new CRISPR/Cas9-based therapies using chimeric antigen receptor T cells (CARTs) and hematopoetic stem cells (HSCs).

More... »

Report: Top 30 pharma companies spent $112B on R&D in 2013

Thursday, December 18, 2014 11:19 AM

The world’s leading 30 pharmaceutical companies spent a combined $112 billion on R&D in 2013, an increase of $723 million over the previous year, according to London-based research and consulting firm GlobalData.

More... »

Sosei acquires Jitsubo, a Japanese peptide technology company

Monday, December 15, 2014 12:37 PM

Sosei Group, a global biopharmaceutical company of Japanese origin, will acquire all existing shares of and underwrite a third-party allocation of new shares of Jitsubo, a Japanese peptide technology company. Jitsubo will become a consolidated subsidiary of the group.

More... »

EFPIA hires Joe Jimenez, CEO of Novartis, as new president

Thursday, December 11, 2014 12:06 PM

EFPIA has appointed Joe Jimenez, CEO of Novartis, as its new president. He will work alongside Dr. Stefan Oschmann, CEO Pharma of Merck, and Marc de Garidel, chairman and CEO of Ipsen, who have been appointed as vice presidents by the board.

More... »

As GSK restructuring cuts 900 jobs in RTP, Parexel absorbs 450 of them in new business unit

Monday, December 8, 2014 01:30 PM

GlaxoSmithKline’s global restructuring was felt sharply in North Carolina this week as it announced plans to cut 900 jobs in Research Triangle Park (RTP), where it has 2,500 employees and contractors working in research and development.

More... »

CenterWatch Data Library
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs